Arcturus Therapeutics Holdings Inc. (ARCT) shares are progressing more than 24 percent on Wednesday morning trade after reporting profit of $117.34 million in the fourth quarter compared to loss of $38.66 million last year. Revenue for the quarter surged to $160.29 million from $5.79 million a year ago.
The late-stage clinical messenger RNA medicines company also announced the completion of full enrollment in the Phase 3 study to evaluate ARCT-154 as a booster vaccine for COVID-19.
Currently, shares are at $18.98, up 22.45 percent from the previous close of $15.50 on a volume of 2,467,836.
For comments and feedback contact: editorial@rttnews.com
Get Access to Premium Stock Alerts with RTT Intelligent Investor.
